The commercial prospects of Definity and Optison, the only two ultrasound contrast media approved for clinical use in the U.S., may be damaged if the FDA moves ahead with plans to require black box warnings for the two echocardiography agents.
The commercial prospects of Definity and Optison, the only two ultrasound contrast media approved for clinical use in the U.S., may be damaged if the FDA moves ahead with plans to require black box warnings for the two echocardiography agents.
The Wall Street Journal reported Monday (Oct. 8) that the FDA is contemplating black box notices warning physicians not to use Definity or Optison for patients with unstable angina, acute heart attack, or unstable cardiopulmonary disease. The list covers most of the patients in the U.S. for whom the ultrasound-enhancing agents are likely to be prescribed. FDA-approved indications for Definity and Optison are limited to the heart.
Definity and Optison are approved for numerous body applications in countries outside the U.S.
The black box warnings will be issued in response to FDA investigations of patient deaths and serious cardiovascular reactions to the microbubble contrast agents, according to the Wall Street Journal. The label will also reportedly instruct physicians to monitor patients' hearts with electrocardiograph for 30 minutes after completing the contrast-enhanced ultrasound exams.
A GE Healthcare spokesperson said the firm and FDA are discussing the label change and implementation strategy for Optison. More than one million doses of Optison have been administered with very few adverse reactions, he said.
For more information, refer to the following stories from the Diagnostic Imaging archives:
Journal Review: AIUM renews crusade to have contrast agents approved for use beyond the heart
Multislice CT and microbubble sonography target inflammation in the small bowel
Ultrasound's future in play: will radiologists remain in the picture?
Multicenter Study Shows Merits of AI-Powered Ultrasound Assessment for Detecting Ovarian Cancer
January 3rd 2025Adjunctive AI offered greater than seven percent increases in sensitivity, specificity, and accuracy for ultrasound detection of ovarian cancer in comparison to unassisted clinicians who lacked ultrasound expertise, according to findings from new international multicenter research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
Ultrasound Device Garners FDA De Novo Nod for Kidney Stone Clearance
November 14th 2024Emerging research demonstrated that the Stone Clear device, which facilitates post-lithotripsy clearance of kidney stone fragments, led to a 70 percent lower risk of relapse in comparison to observation in a control group.